[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335968-105":59,"doc-detail-335968-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-role-of-cxcl1-in-crosstalk-between-endocrine-resistant-breast-cancer-and-fibroblast","The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast","","Endocrine resistant, estrogen receptor–positive (ER+) breast cancer remains challenging despite effective endocrine therapies, as drug resistance and tumor recurrence lead to poor outcomes. This study investigates CXCL1 as a secreted mediator of communication between endocrine resistant breast cancer (ERBC) cells and fibroblasts. Using four ERBC cell lines, protein array and qRT-PCR/U-Plex confirm CXCL1 upregulation. Co-culture enhances ERBC growth and migration, with ERK/MAPK pathway activation. Reparixin, a CXCR1/2 inhibitor, attenuates signaling and inhibits ERBC growth.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-role-of-cxcl1-in-crosstalk-between-endocrine-resistant-breast-cancer-and-fibroblast/335968/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-role-of-cxcl1-in-crosstalk-between-endocrine-resistant-breast-cancer-and-fibroblast/335968.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the study address about endocrine resistant breast cancer?","Question",{"text":113,"@type":114},"The study examines how CXCL1 mediates communication between endocrine resistant breast cancer cells and fibroblasts, and how this crosstalk supports tumor growth and metastatic behavior.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do the researchers determine CXCL1 is involved in ERBC–fibroblast communication?",{"text":118,"@type":114},"Protein array shows CXCL1 upregulation, and CXCL1 expression is validated using real-time qRT-PCR and a U-Plex assay.",{"name":120,"@type":111,"acceptedAnswer":121},"What therapeutic strategy is tested to counter endocrine resistance signals?",{"text":122,"@type":114},"Reparixin inhibits the CXCR1/2 receptors and attenuates ERK/MAPK activation, and combining reparixin with CDK4/6 inhibitors (palbociclib and ribociclib) increases growth inhibition.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335968,1790181615,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":4},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Molecular Biology Reports (2024) 51:331  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1033-023-09119-4  \nThe role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast  \nSneha Pandithar1 · Daniel Galke1 · Ahone Akume1 · Artem Belyakov1 · Dominick Lomonaco1 · Amirah A. Guerra1 · Jay Park1 · Olivia Reff1 · Kideok Jin1  \nReceived: 17 January 2023 / Accepted: 6 December 2023 / Published online: 23 February 2024 © The Author(s) 2024  \nAbstract  \nBackground ER positive breast cancer is currently targeted using various endocrine therapies. Despite the proven therapeutic efficacy, resistance to the drug and reoccurrence of tumor appears to be a complication that many patients deal with. Molecular pathways underlying the development of resistance are being widely studied.  \nMethods and results In this study, using four established endocrine resistant breast cancer (ERBC) cell lines, we characterized CXCL1 as a secreted factor in crosstalk between ERBC cells and fibroblasts. Protein array revealed upregulation of CXCL1 and we confirmed the CXCL1 expression by real-time qRT-PCR and U-Plex assay. Co-culturing ERBC cells with fibroblasts enhanced the cell growth and migration compared to monoculture. The crosstalk of ERBC cells with fibroblasts significantly activates ERK/MAPK signaling pathway while reparixin, CXCR1/2 receptor inhibitor, attenuates the activity. Reparixin displayed the ERBC cell growth inhibition and the combination treatment with reparixin and CDK4/6 inhibitor (palbociclib and ribociclib) increased these inhibitory effect.  \nConclusions Taken together, our study implicates CXCL1 as a critical role in ERBC growth and metastasis via crosstalk with fibroblast and cotargeting CXCR1/2 and CDK4/6 could potentially overcome endocrine resistant breast cancer.  \nKeywords Breast cancer · Endocrine resistance · CXCL1 · Fibroblast  \nIntroduction  \nAround 70% of breast cancer tissue express estrogen receptor alpha [1] . This subset of breast cancer can be treated by endocrine therapy that exploits the cancer’s dependence on hormone signaling for survival, proliferation, and progression. Expression of this molecule allows for endocrine specific targeting of oncogenic pathways. Therapy mechanisms for estrogen receptor include aromatase inhibitors to decrease estrogen ligand, ovarian suppression to decrease estrogen circulation, inhibiting ligand-receptor interactions using selective estrogen receptor modulators (SERMs), or degrading estrogen receptor using selective estrogen receptor down regulators (SERDs) [1] . Endocrine therapy is an effective treatment with cure rates of 50% of patients and  \n* Kideok Jin [kideok.jin@acphs.edu](kideok.jin@acphs.edu)  \n1 Department of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, BRB Room 105B, Albany, NY 12208, USA  \nclinical benefit in those with advanced/metastatic stages [2] . However, endocrine resistance can arise and is associated with significant morbidity and mortality.  \nMechanisms of endocrine resistance involve different levels of regulation of growth signaling pathways in the cell. Estrogen receptor downstream signaling pathways are interconnected with other kinase signaling pathways and crosstalk allows for amplification or reduction of signaling to bypass ER blockade, providing the cell with alternative proliferation and survival signals or regulation of ER activity and/or signaling. Post-translational modifications of the estrogen receptor can activate downstream pathways by alteration of the ER, coregulators or other machinery involved in the pathway. Due to inherent genomic instability in cancer, mutations can occur in ESR1 that may promote expression, ligand affinity or confer constitutive activation in absence of ligand [1, 2] .  \nThe tumor microenvironment (TME) is a crucial factor in determination of anti-cancer immunity and cancer survival, proliferation and progression. TME alterations t","cbCaiovP5Sc46O9E","https://ap.wps.com/l/cbCaiovP5Sc46O9E","pdf",1423717,"English","# Abstract\n# Background\n# Methods and results\n## CXCL1 upregulation and ERBC–fibroblast crosstalk\n## Functional effects on growth, migration, and signaling\n## Pharmacologic modulation with reparixin and CDK4/6 inhibitors\n# Conclusions\n# Keywords\n# Introduction\n## Endocrine therapy and resistance in ER+ breast cancer\n## Tumor microenvironment and fibroblast roles\n## CXCL1 inflammatory regulation and pro-cancer functions\n# Results\n## Co-culture effects on proliferation and migration","[{\"question\":\"What question does the study address about endocrine resistant breast cancer?\",\"answer\":\"The study examines how CXCL1 mediates communication between endocrine resistant breast cancer cells and fibroblasts, and how this crosstalk supports tumor growth and metastatic behavior.\"},{\"question\":\"How do the researchers determine CXCL1 is involved in ERBC–fibroblast communication?\",\"answer\":\"Protein array shows CXCL1 upregulation, and CXCL1 expression is validated using real-time qRT-PCR and a U-Plex assay.\"},{\"question\":\"What therapeutic strategy is tested to counter endocrine resistance signals?\",\"answer\":\"Reparixin inhibits the CXCR1/2 receptors and attenuates ERK/MAPK activation, and combining reparixin with CDK4/6 inhibitors (palbociclib and ribociclib) increases growth inhibition.\"}]","The role of CXCL1 in crosstalk between endocrine resistant breast cancer and fibroblast | PDF",1790012983]